Semirigid thoracoscopic pleura ablasion versus galc pleurodesisin the treatment of malignant pleural effusion: a prospective, randomised, controlled trial

Semirigid thoracoscopic pleura ablasion versus galc pleurodesisin the treatment of malignant pleura

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005330

Enrollment

Unknown

Registered

2014-09-24

Start date

2014-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant pleural effusion

Interventions

A:Semirigid thoracoscopic pleura ablasion

B:thoracoscopic galc pleurodesisin

C:Semirigid thoracoscopic pleura ablasion with galc

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged more than 18 years; 2. according to the thediagnosis of malignant pleural effusion; 3. Signed the informed consent; 4. without contraindication to galc or operation; 5. comply with follow-up.

Exclusion criteria

Exclusion criteria: We will exclude patients with uncontrolled bleeding tendencies, an unstable cardiovascular status or severe heart failure, persistent hypoxemia, extreme weakness and not comply with follow-up.

Design outcomes

Primary

Measure	Time frame
effective rate;survival time;Mortality;	—

Countries

China

Contacts

Public ContactZhou-Gui Ling

lzg228@163.com+86 13877217374

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026